who created semaglutide Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients The story of semaglutide

The unfolding tapestry of non-adherence, particularly in the realm of Wegovy administration, elegantly entwines with the diminution of potential weight loss outcomes

GLP-1 impact on psychostimulant and nicotine reward Considering that the mesolimbic reward system is a key target not only for food and alcohol, but also for psychostimulants and nicotine (Koob, 1992), it is perhaps not surprising that recent work has explored the potential of GLP-1 analogs to alter psychostimulant reward

Akoumianakis I, Antoniades C

The classical titration spans four weeks, reaching 1mg by Week 4

Once it does its job, it becomes oxidized